A competing-risks nomogram for sarcoma-specific death following local recurrence

被引:85
作者
Kattan, MW
Heller, G
Brennan, MF
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA
关键词
competing risks; conditional cumulative incidence function; nomogram; spline estimation;
D O I
10.1002/sim.1574
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The majority of staging systems focus on the definition of stage, and, therefore, prediction of prognosis. In the current era of clinical trial research, it has become apparent that the clinical stage alone is not sufficient to assess patient risk of treatment failure. As the number of biological markers increases, our ability to partition the traditional disease classification system improves, and our ability to predict patient success continues to increase. One approach to quantifying individual patient risk is through the nomogram. Nomograms are graphical representations of statistical models, which provide the probability of treatment outcome based on patient-specific covariates. We will focus on the use of the nomogram when the response variable is time to failure and there are multiple, possibly dependent, competing causes of failure. In this setting, estimation of the failure probability through direct application of the Cox proportional hazards model provides the probability of failure (for example, death from cancer) assuming failure from a dependent competing cause will not occur. In many clinical settings this is an unrealistic assumption. The purpose of this study is to illustrate the use of the conditional cumulative incidence function for providing a patient-specific prediction of the probability of failure in the setting of competing risks. A competing risks nomogram is produced to estimate the probability of death due to sarcoma for patients who have already developed a local recurrence of their initially treated soft-tissue sarcoma. Copyright (C) 2003 John Wiley Sons, Ltd.
引用
收藏
页码:3515 / 3525
页数:11
相关论文
共 19 条
[1]   Pulmonary metastases from soft tissue sarcoma - Analysis of patterns of disease and postmetastasis survival [J].
Billingsley, KG ;
Burt, ME ;
Jara, E ;
Ginsberg, RJ ;
Woodruff, JM ;
Leung, DHY ;
Brennan, MF .
ANNALS OF SURGERY, 1999, 229 (05) :602-612
[2]   APPROXIMATE CASE INFLUENCE FOR THE PROPORTIONAL HAZARDS REGRESSION-MODEL WITH CENSORED-DATA [J].
CAIN, KC ;
LANGE, NT .
BIOMETRICS, 1984, 40 (02) :493-499
[3]   Validation studies for models projecting the risk of invasive and total breast cancer incidence [J].
Costantino, JP ;
Gail, MH ;
Pee, D ;
Anderson, S ;
Redmond, CK ;
Benichou, J ;
Wieand, HS .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (18) :1541-1548
[4]   Competing approaches to analysis of failure times with competing risks [J].
Farley, TMM ;
Ali, MM ;
Slaymaker, E .
STATISTICS IN MEDICINE, 2001, 20 (23) :3601-3610
[5]  
Fine J P, 2001, Biostatistics, V2, P85, DOI 10.1093/biostatistics/2.1.85
[6]   A proportional hazards model for the subdistribution of a competing risk [J].
Fine, JP ;
Gray, RJ .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) :496-509
[7]   Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study [J].
Fisher, B ;
Costantino, JP ;
Wickerham, DL ;
Redmond, CK ;
Kavanah, M ;
Cronin, WM ;
Vogel, V ;
Robidoux, A ;
Dimitrov, N ;
Atkins, J ;
Daly, M ;
Wieand, S ;
Tan-Chiu, E ;
Ford, L ;
Wolmark, N .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1371-1388
[8]   DEVELOPMENT AND TREATMENT OF PULMONARY METASTASES IN ADULT PATIENTS WITH EXTREMITY SOFT-TISSUE SARCOMA [J].
GADD, MA ;
CASPER, ES ;
WOODRUFF, JM ;
MCCORMACK, PM ;
BRENNAN, MF .
ANNALS OF SURGERY, 1993, 218 (06) :705-712
[9]  
Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.3.CO
[10]  
2-F